Dividend Declaration

BioPharma Credit PLC
19 September 2024
 

19 September 2024

 

BIOPHARMA CREDIT PLC 

("BIOPHARMA CREDIT" OR THE "COMPANY") 

ORDINARY AND SPECIAL DIVIDEND DECLARATION

3.79 CENT PER SHARE DISTRIBUTION INCLUDING A 2.04 CENT SPECIAL DISTRIBUTION

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to declare an interim dividend in respect of the quarterly financial period ending 30 September 2024 of 3.75 cents per share.  BPCR will also be declaring an interim dividend for the calendar year ending 31 December 2023 of 0.039155 cents per ordinary share to distribute the remaining revenue reserves for the calendar year 2023.  Both interim dividends will be payable on 29 October 2024 to ordinary shareholders on the register as at 27 September 2024. The 3.789155 cents dividend comprises an ordinary dividend of 1.75 cents and a special dividend of 2.039155 cents. The ex-dividend date will be 26 September 2024.

The Company is currently paying and continues to target a 7 cent annual dividend per ordinary share, enhanced by variable special dividends that comprise the excess earnings of the Company in 2024 thus far. After the payment of both interim dividends on 29 October 2024, dividends for the calendar year 2024 to date will total 7.289155 cents. 

The Company has chosen to designate the entire amount of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company.

The default payment for dividends is in US dollars. However, shareholders can elect to have dividends paid in sterling (GBP) and the option to elect a sterling dividend payment for this dividend will be available to shareholders until 27 September 2024 (the "Election Date").

Further details together with a copy of the Dividend Currency Election Form, which should be sent to Link Group, 10th Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL when completed, will be available on the Group's website shortly at www.bpcruk.com/investor-materials. CREST shareholders must elect via CREST. Further details together with a copy of the Dividend Currency Election Form, which should be sent to Link Group, 10th Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL when completed, will be available on the Group's website shortly at www.bpcruk.com/investor-materials. CREST shareholders must elect via CREST.

Enquiries:

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0) 1392 477 500

Burson Buchanan

Mark Court / Jamie Hooper / Henry Wilson / Samuel Adams

+44 (0) 20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100